Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection-Reference-Cited by-全球学者库

Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection

Published:2022-11 Issue: Volume:156 Page:105273
ISSN:1386-6532
Container-title:Journal of Clinical Virology
language:en
Short-container-title:Journal of Clinical Virology

Author:

Cheng Samuel SM,Mok Chris KP,Li John KC,Ng Susanna S,Lam Bosco HS,Jeevan Trushar,Kandeil Ahmed,Pekosz Andrew,Chan Karl CK,Tsang Leo CH,Ko Fanny W,Chen Chunke,Yiu Karen,Luk Leo LH,Chan Ken KP,Webby Richard J,Poon Leo LM,Hui David SC,Peiris Malik^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Virology

Reference23 articles.

1. Protection of SARS-CoV-2 natural infection against reinfection with the BA.4 or BA.5 Omicron subvariants;Altarawneh;medRxiv,2022

2. Effects of previous infection and vaccination on symptomatic omicron infections;Altarawneh;N. Engl. J. Med.,2022

3. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines;Bowen;Science,2022

4. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection;Cao;Nature,2022

5. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization;Cele;Nature,2022

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential inhibition of SARS-CoV-2 infection and its mutation with the novel geldanamycin analogue: Ignaciomycin;Arabian Journal of Chemistry;2024-02

2. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination;Heliyon;2024-01

3. Development of a novel medium throughput flow-cytometry based micro-neutralisation test for SARS-CoV-2 with applications in clinical vaccine trials and antibody screening;PLOS ONE;2023-11-30

4. Evolution of protective SARS-CoV-2-specific B- and T-cell responses upon vaccination and Omicron breakthrough infection;2023-10-06

5. Epidemiologic Characteristics of SARS-CoV-2 Omicron BA.5.1.3 Variant and the Protection Provided By Inactivated Vaccination;Viral Immunology;2023-10-01